Zealand Pharma: diabetes drug meets endpoints; shares rise
(CercleFinance.com) - Zealand Pharma said its anti-diabetic treatment has met its primary and key secondary endpoints in a late-stage pediatric trial, which has sent the Danish biotechnology company's shares up 6% in Tuesday afternoon trading.
The study's primary endpoint found that the median time to blood glucose recovery was 10 minutes for Zealand's dasiglucagon, which was superior to placebo (median: 30 minutes).
Invented and developed by Zealand, dasiglucagon is being developed in a ready-to-use self-injection rescue pens for fast treatment of severe hypoglycemia in people with diabetes.
Note that 42 children, aged 6 to 17, were enrolled in this Phase 3 trial.
Zealand has said that these positive results keep the company on track for submitting a new drug application to the US FDA in early 2020.
Its shares are currently up 6.5% in Copenhagen.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The study's primary endpoint found that the median time to blood glucose recovery was 10 minutes for Zealand's dasiglucagon, which was superior to placebo (median: 30 minutes).
Invented and developed by Zealand, dasiglucagon is being developed in a ready-to-use self-injection rescue pens for fast treatment of severe hypoglycemia in people with diabetes.
Note that 42 children, aged 6 to 17, were enrolled in this Phase 3 trial.
Zealand has said that these positive results keep the company on track for submitting a new drug application to the US FDA in early 2020.
Its shares are currently up 6.5% in Copenhagen.
Copyright (c) 2019 CercleFinance.com. All rights reserved.